Gilead Sciences, headquartered in Foster City, California, employs 18,000 people and focuses on developing medicines for HIV, hepatitis, COVID-19, and cancer. Its portfolio includes numerous marketed products and several promising candidates.
GILD has been in the news recently: Gilead Sciences' FDA-approved HIV injection, Yeztugo, is the first twice-yearly prevention option for adults and adolescents weighing at least 35 kg, priced at $28,218 annually. This new injectable treatment offers a more convenient alternative to existing HIV medications.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
